Quick Reference Chart

This table is not intended to replace medical judgment.

Brand Name	Generic Name	Ages	Loading Dose	Maintenance Dose	Mechanism of Action
PSORIASIS
Enbrel*	Etanercept	PsA 18 yrs + PsO 4 yrs +	50 mg twice weekly for 12 wks	50 mg q wk	TNF-α blocker
Enbrel*	Etanercept	PsA 18 yrs + PsO 4 yrs +	PEDS: 0.8 mg/kg q wk (max-dose 50 mg q wk)		TNF-α blocker
Humira*	Adalimumab	PsO / PsA 18 yrs +	80 mg on Day 1 and then 40 mg on Day 8	40 mg q2 wks	TNF-α blocker
Remicade*	lnfliximab	PsO / PsA 18 yrs +	5 mg/kg IV wk 0, 2, and 6	5 mg/kg IV q8 wks	TNF-α blocker
Cimzia*	Certolizumab Pegol	PsO / PsA 18 yrs +	>90 kg: no loading dose	400 mg q2 wks	TNF-α blocker
Cimzia*	Certolizumab Pegol	PsO / PsA 18 yrs +	≤90 kg: 400 mg at wk 0, 2 and 4	200 mg q2 wks	TNF-α blocker
Bimzelx*	Bimekizumab	PsO / PsA 18 yrs +	320 mg at wk 0, 4, 8, 12, and 16	320 mg q8 wks (for patients ≥ 120 kg, consider 320 mg q4 wks after wk 16)	IL-17A and F antagonist
Cosentyx*	Secukinumab	PsA 2 yrs + PsO 6 yrs +	300 mg SQ at wk 0, 1, 2, 3, and 4	300 mg SQ q4 wks	IL-17A antagonist
Cosentyx*	Secukinumab	PsA 2 yrs + PsO 6 yrs +	PEDS: Dosage based on body weight and administered at wks 0, 1, 2, 3, and 4 and q4 wks <50 kg = 75 mg \| ≥50 kg = 150 mg		IL-17A antagonist
Taltz*	lxekizumab	PsA 18 yrs + PsO 6 yrs +	160 mg at wk 0, then 80 mg at wk 2, 4, 6, 8, 10, and 12	80 mg q4 wks	IL-17A antagonist
Taltz*	lxekizumab	PsA 18 yrs + PsO 6 yrs +	PEDS: >50 kg = 160 mg at wk 0 then 80 mg q4 wks \| 25 to 50 kg = 80 mg at wk 0 then 40 mg q4 wks \| <25 kg = 40 mg at wk 0 then 20 mg q4 wks		IL-17A antagonist
Siliq	Brodalumab	PsO 18 yrs +	210 mg at wk 0, 1, and 2	210 mg q2 wks	IL-17A receptor antagonist
Stelara*	Ustekinumab	PsA 6 yrs + PsO 6 yrs +	≤100 kg: 45 mg at wk 0 and 4	45 mg q12 wks	IL-12 and IL-23 antagonist
			>100 kg: 90 mg at wk 0 and 4	90 mg q12 wks
			PEDS: Weight-based dosing recommended at initial dose, 4 weeks later, then q12 weeks. Less than 60 kg = 0.75 mg/kg \| 60 kg to 100 kg = 45 mg \| Greater than 100 kg = 90 mg
Tremfya*	Guselkumab	PsO / PsA 6 yrs + (weighing ≥40 kg)	100 mg at wk 0 and 4	100 mg q8 wks	IL-23 antagonist
llumya	Tildrakizumab	PsO 18 yrs +	100 mg at wk 0 and 4	100 mg q12 wks	IL-23 antagonist
Skyrizi*	Risankizumab	PsO / PsA 18 yrs +	150 mg at wk 0 and 4	150 mg q12 wks	IL-23 antagonist
Spevigo (GPP)	Spesolimab	12 yrs + (weighing ≥40 kg)	For treatment of flare: 900 mg IV Not experiencing a flare: 600 mg SQ	For treatment of flare: Repeat in one week if flare persists Not experiencing a flare: 300 mg SQ q4 weeks (SQ use after IV dose for flare treatment: Initiate or reinitiate at 300 mg SQ q4 weeks; no loading dose req’d)	IL-36 receptor antagonist
HIDRADENITIS SUPPURATIVA
Humira	Adalimumab	12 yrs +	Day 1: 160 mg (given in one day or split over 2 consecutive days); Day 15: 80 mg; Day 29: 40 mg q wk or 80 mg q2 wk	40 mg q wk or 80 mg q2 wks	TNF-α blocker
Humira	Adalimumab	12 yrs +	PEDS: 30 kg to <60 kg: Day 1: 80 mg; Day 8: 40 mg TNF-α blocker >60 kg: Day 1: 160 mg (given in one day or split over 2 consecutive days); Day 15: 80 mg; Day 29 and subsequent doses: 40 mg q wk or 80 mg q2 wks	PEDS: 30 kg to <60 kg: 40 mg q2 wks >60 kg: 40 mg q wk or 80 mg q2 wks	TNF-α blocker
Cosentyx	Secukinumab	12 yrs +	300 mg at wk 0, 1, 2, 3, and 4	300 mg q4 wks; if inadequate response 300 mg q2 wks may be considered	IL-17A antagonist
Cosentyx	Secukinumab	12 yrs +	PEDS: Dosage based on body weight and administered at wks 0, 1, 2, 3, and 4, then q4 wks ≥30 kg to <90 kg=150 mg ≥90 kg=300 mg		IL-17A antagonist
Bimzelx	Bimekizumab	18 yrs +	320 mg at wk 0, 2, 4, 6, 8, 10, 12, 14, and 16	320 mg q4 wks	IL-17A and F antagonist
ATOPIC DERMATITIS
Dupixent	Dupilumab	6 mos +	600 mg	300 mg SQ q2 wk	IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)
Dupixent	Dupilumab	6 mos +	PEDS 6m–5y: 5 to <15 kg = 200 mg q4 wks \| 15 to <30 kg = 300 mg q4 wks PEDS 6y–17y: 15 to <30 kg = 600 mg then 300 mg q4 wks \| 30 to <60 kg = 400 mg then 200 mg q2 wks \| ≥60 kg = 600 mg then 300 mg q2 wks		IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)
Ebglyss	Lebrikizumab	12 yrs + (weighing ≥40 kg)	500 mg at wk 0 and 2, then 250 mg q2 wks until 16 wks or later, when adequate clinical response is achieved	250 mg q4 wks	IL-13 antagonist
Adbry	Tralokinumab	12 yrs +	Adults: 600 mg	Adults: 300 mg q2 wks; after 16 wks, q4 wks may be considered for adults <100 kg who achieve clear or almost clear skin	IL-13 antagonist
Adbry	Tralokinumab	12 yrs +	PEDS 12y-17y: 300 mg	PEDS 12y-17y: 150 mg q2 wks	IL-13 antagonist
Nemluvio	Nemolizumab	12 yrs +	60 mg	30 mg q4 wks; for patients achieving clear or almost clear skin at 16 wks, 30 mg q8 wks recommended. Use with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies	IL-31 receptor antagonist
PRURIGO NODULARIS
Dupixent	Dupilumab	18 yrs +	600 mg	300 mg q2 wks	IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)
Nemluvio	Nemolizumab	18 yrs +	60 mg	Adults weighing ≥90 kg: 60 mg q4 wks Adults weighing <90 kg: 30 mg q4 wks	IL-31 receptor antagonist
CHRONIC SPONTANEOUS URTICARIA
Xolair	Omalizumab	12 yrs +	None	150 mg or 300 mg q4 wks	anti-IgE antibody
Dupixent	Dupilumab	2 yrs +	600 mg	300 mg q2 wks	IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)
Dupixent	Dupilumab	2 yrs +	PEDS 2y-5y: None PEDS 6y-17y: 15 to <30 kg = 600 mg \| 30 to <60 kg = 400 mg \| ≥60 kg: 600 mg	PEDS 2y-5y: 5 to <15 kg = 200 mg q4 wks \| 15 to <30 kg = 300 mg q4 wks PEDS 6y-17y: 15 to <30 kg = 300 mg q4 wks \| 30 to <60 kg = 200 mg q2 wks \| ≥60 kg: 300 mg q2 wks	IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)
BULLOUS PEMPHIGOID
Dupixent	Dupilumab	18 yrs +	600 mg	300 mg q2 wks; use in combination with tapering course of oral corticosteroids	IL-4 receptor-α antagonist (inhibits IL-4 and IL-13)

SQ = subcutaneous, q = every, wk/W = weeks,

PsO = psoriasis, PsA = psoriatic arthritis, PEDS = pediatric dosing,

GPP = generalized pustular psoriasis

PN = prurigo nodularis

CSU=chronic spontaneous urticaria

BP = bullous pemphigoid

*FDA approved to treat both psoriasis and psoriatic arthritis.

DISCLAIMER: The dosages seen in this chart were obtained from the respective FDA approved package inserts for psoriasis, hidradenitis suppurativa, atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. This chart is for reference only and not to be substituted for clinical judgment. The authors are not responsible for treatment decisions or outcomes based on the information in this chart.

Check out more tools

Explore our suite of free tools to elevate your practice